Investor Relations

Investors

Investor Relations

Corporate Profile

Anpac Bio is a biotechnology company focusing on early cancer screening and detection and marketing a suite of cancer detection tests, including CDA (cancer differentiation analysis), bio-chemistry, immunology, and genomics tests. Anpac has developed a multi-cancer screening and detection test that uses innovative, patented CDA technology and proprietary cancer-detection device.

Press Releases

Dec 14, 2020

AnPac Bio Makes Significant Progress in Detecting Pre-cancer Diseases and Recorded Over 20 Types of Pre-cancer Diseases

SAN JOSE, Calif., Dec. 14, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today it has made significant

Dec 04, 2020

Anpac Bio Announces Change of Auditor

SAN JOSE, Dec. 04, 2020 (GLOBE NEWSWIRE) -- Anpac Bio-Medical Science Co., Ltd. (“Anpac Bio,” the “Company” or “we”) (ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today the resignation of Ernst & Young Hua

Nov 25, 2020

AnPac Bio Sets Record Test Volume in Q3, and Forecasts ~ 100% Revenue Growth in 2020

SAN JOSE, Calif., Nov. 25, 2020 (GLOBE NEWSWIRE) -- AnPac Bio-Medical Science Co., Ltd. (“AnPac Bio,” the “Company” or “we”) (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, announced today that it experienced

Stock Quote

Change

Volume

52 Week High

52 Week Low

Jan 22, 2021 2:08 PM EST

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Events

AnPac Bio First Six Months 2020 Financial Results

Sep 10, 2020 at 8:00 AM EDT

View Webcast

Investors

Investor Relations

Corporate Profile

Stock Quote

Quick Links

Contact Information